Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 3/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15529807 | 0.87 | GSK3B (0.48) | MAP2K4DAOGSK3BALDH1A1PARP1 | |
| SCHEMBL30548014 | 0.87 | GSK3B (0.48) | MAP2K4DAOGSK3BALDH1A1PARP1 | |
| SCHEMBL11147948 | 0.78 | GRIN2D (0.39) | DAOGSK3BALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL11777519 | 0.76 | GSK3B (0.43) | MAP2K4DAOGSK3BALDH1A1PARP1 | |
| SCHEMBL15332567 | 0.76 | FADS1 (0.49) | GSK3BCHEK1LMNAPDPK1JAK2 | |
| SCHEMBL30548017 | 0.76 | FADS1 (0.49) | GSK3BCHEK1LMNAPDPK1JAK2 | |
| SCHEMBL25430355 | 0.75 | LMNA (0.46) | DAOALDH1A1PARP1CHEK1LMNA | |
| SCHEMBL29348065 | 0.75 | PARP1 (0.47) | DAOALDH1A1PARP1CHEK1LMNA | |
| SCHEMBL3593032 | 0.75 | MAP2K4 (0.50) | MAP2K4DAOGSK3BALDH1A1PARP1 | |
| SCHEMBL14738828 | 0.75 | MAP2K4 (0.63) | MAP2K4DAOGSK3BALDH1A1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313376-B1 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-12-24 | — | — | EP | disclosed |
| EP-2417111-B1 | SUBSTITUTED 1-ALKYLCINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION OF SAME | SANOFI SA (FR) | 2014-06-04 | — | — | EP | disclosed |
| US-8420651-B2 | Substituted 1-alkylcinnolin-4(1H)-one derivatives, preparation thereof and therapeutic application of same | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-8410099-B2 | Substituted 1-benzyl-cinnolin-4(1H)-one derivatives, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2013-04-02 | — | — | US | disclosed |
| US-20120129864-A1 | SUBSTITUTED 1-ALKYLCINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION OF SAME | SANOFI (FR) | 2012-05-24 | — | — | US | disclosed |
| US-20110144115-A1 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| EP-2313376-A2 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010004215-A2 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129864-A1 | SUBSTITUTED 1-ALKYLCINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION OF SAME | ALK, CBR1, CBR3 | MAP2K4 2389/4885DAO 1150/4885GSK3B 3310/4885 |
| US-20110144115-A1 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CNR1, CNR2, GPR18 | MAP2K4 3367/4885DAO 3558/4885GSK3B 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.